REGENXBIO (RGNX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.43
- Estimate
- -$0.11
- Surprise
- +499.2%
- Revenue (period 2026-06-30)
- $108.0M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
REGENXBIO (RGNX) beat the -$0.11 estimate with adjusted EPS of $0.43 — a large 499.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RGNX Sell at 5.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +499.2% surprise compares with a +107.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: lead product candidates
- DATA_ISSUE: analyst_target_implausible (raw $23.58 vs price $7.13 — ratio 3.3×). Rejected, falling back to technical TP.
- Quality below floor (3.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.13
- Price target
- $8.39
- Stop
- $6.90
- Upside to target
- +17.7%
Model outputs from TrendMatrix’s engine as of 2026-10-13 — shown for context, not personalized investment advice.
RGNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $512.9M
- P/E (fwd)
- -2.6
- 52-week range
- $5.46–$16.19
- Off 52-week high
- 56.0%
- RSI (14)
- 44
- Volume vs avg
- 0.46×
- Score today
- 5.5/10